This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halin, C. Articles by Neri, D. Search for Related Content PubMed PubMed Citation Articles by Halin, C. Articles by Neri, D.

Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor ¹

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, CH-8057 Zurich, Switzerland [C. H., V. G., M. E. V., D. N.]; Laboratory of Cell Biology, Istituto Nazionale per la Ricerca sul Cancro, I-16132 Genoa, Italy [L. B., L. Z.]; Institute of Pathology, Friedrich Schiller University, D-07740 Jena, Germany [A. B.]; and Institute of Pathology, HELIOS-Klinikum, Erfurt, Germany [H. K.]

The potent antitumor activity of certain cytokines is often achieved at the expense of unacceptable toxicity. One avenue to improve the therapeutic index of cytokines in cancer therapy consists of fusing them to monoclonal antibodies capable of a selective localization at the tumor site. We have constructed fusion proteins of interleukin-12 (IL-12) and tumor necrosis factor (TNF-) with L19, an antibody fragment specific to the extradomain B of fibronectin which has been shown to target tumors in animal models and in patients with cancer. These fusions display a potent antitumor activity in several immunocompetent murine models of cancer but do not lead to complete remissions of established aggressive tumors. In this article, we have evaluated the tumor-targeting properties and the anticancer activities of combinations of the two antibody-cytokine fusion proteins, as well as of a triple fusion protein between IL-12, L19, and TNF-. Although all fusion proteins were active in vitro, the triple fusion protein failed to localize to tumors in vivo and to show significant therapeutic effects. By contrast, the combination of IL-12-L19 and L19-TNF- displayed potent synergistic anticancer activity and led to the eradication of F9 teratocarcinomas grafted in immunocompetent mice. When cured mice were rechallenged with tumor cells, a delayed onset of tumor growth was observed, indicating the induction of a partial antitumor vaccination effect. Potent anticancer effects were achieved at doses of IL-12-L19 and L19-TNF- (2 µg + 2 µg/mouse), which were at least 5-fold lower than the maximal-tolerated dose. The combined administration of the two fusion proteins showed only a modest increase in toxicity, compared with treatments performed with the individual fusion proteins. These results show that the targeted delivery of cytokines to the tumor environment strongly potentiates their antitumor activity and that the combination treatment with IL-12-L19 and L19-TNF- appears to be synergistic in vivo.

This article has been cited by other articles:

				C. Schliemann, A. Palumbo, K. Zuberbuhler, A. Villa, M. Kaspar, E. Trachsel, W. Klapper, H. D. Menssen, and D. Neri Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Blood, March 5, 2009; 113(10): 2275 - 2283. [Abstract] [Full Text] [PDF]

				J. Marlind, M. Kaspar, E. Trachsel, R. Sommavilla, S. Hindle, C. Bacci, L. Giovannoni, and D. Neri Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy Clin. Cancer Res., October 15, 2008; 14(20): 6515 - 6524. [Abstract] [Full Text] [PDF]

				A. Krippner-Heidenreich, I. Grunwald, G. Zimmermann, M. Kuhnle, J. Gerspach, T. Sterns, S. D. Shnyder, J. H. Gill, D. N. Mannel, K. Pfizenmaier, et al. Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity J. Immunol., June 15, 2008; 180(12): 8176 - 8183. [Abstract] [Full Text] [PDF]

				H. Wang, K. Chen, W. Cai, Z. Li, L. He, A. Kashefi, and X. Chen Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein Mol. Cancer Ther., May 1, 2008; 7(5): 1044 - 1053. [Abstract] [Full Text] [PDF]

				M. Kaspar, E. Trachsel, and D. Neri The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis Cancer Res., May 15, 2007; 67(10): 4940 - 4948. [Abstract] [Full Text] [PDF]

				D. Berndorff, S. Borkowski, D. Moosmayer, F. Viti, B. Muller-Tiemann, S. Sieger, M. Friebe, C. S. Hilger, L. Zardi, D. Neri, et al. Imaging of Tumor Angiogenesis Using 99mTc-Labeled Human Recombinant Anti-ED-B Fibronectin Antibody Fragments J. Nucl. Med., October 1, 2006; 47(10): 1707 - 1716. [Abstract] [Full Text] [PDF]

				S. Bauer, N. Adrian, E. Fischer, S. Kleber, F. Stenner, A. Wadle, N. Fadle, A. Zoellner, R. Bernhardt, A. Knuth, et al. Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins J. Immunol., August 15, 2006; 177(4): 2423 - 2430. [Abstract] [Full Text] [PDF]

				S. S. Brack, M. Silacci, M. Birchler, and D. Neri Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin. Cancer Res., May 15, 2006; 12(10): 3200 - 3208. [Abstract] [Full Text] [PDF]

				E. Balza, L. Mortara, F. Sassi, S. Monteghirfo, B. Carnemolla, P. Castellani, D. Neri, R. S. Accolla, L. Zardi, and L. Borsi Targeted Delivery of Tumor Necrosis Factor-{alpha} to Tumor Vessels Induces a Therapeutic T Cell-Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin Clin. Cancer Res., April 15, 2006; 12(8): 2575 - 2582. [Abstract] [Full Text] [PDF]

				G. Helguera, J. A. Rodriguez, and M. L. Penichet Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol. Cancer Ther., April 1, 2006; 5(4): 1029 - 1040. [Abstract] [Full Text] [PDF]

				Z. Li, R. Zhao, X. Wu, Y. Sun, M. Yao, J. Li, Y. Xu, and J. Gu Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics FASEB J, December 1, 2005; 19(14): 1978 - 1985. [Abstract] [Full Text] [PDF]

				Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern Cancer Res., February 1, 2005; 65(3): 1063 - 1070. [Abstract] [Full Text] [PDF]

				H. Shibata, Y. Yoshioka, S. Ikemizu, K. Kobayashi, Y. Yamamoto, Y. Mukai, T. Okamoto, M. Taniai, M. Kawamura, Y. Abe, et al. Functionalization of Tumor Necrosis Factor-{alpha} Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window Clin. Cancer Res., December 15, 2004; 10(24): 8293 - 8300. [Abstract] [Full Text] [PDF]